- Research article
- Open Access
A prospective longitudinal in vivo 1H MR spectroscopy study of the SIV/macaque model of neuroAIDS
© Fuller et al; licensee BioMed Central Ltd. 2004
Received: 26 November 2003
Accepted: 05 March 2004
Published: 05 March 2004
The neurological complications of HIV infection remain poorly understood. Clinically, in vivo 1H magnetic resonance spectroscopy (MRS) demonstrates brain injury caused by HIV infection even when the MRI is normal. Our goal was to undertsand the dynamics of cerebral injury by performing a longitudinal in vivo 1H MRS study of the SIV/macaque model of neuroAIDS.
Eight rhesus macaques were infected with SIVmac251 and serially imaged with MRI and 1H MRS to terminal AIDS or the endpoint of 2 years. During acute infection, there were stereotypical brain MRS changes, dominated by a significant elevation of the Cho/Cr ratio in the frontal cortex. Subsequently, brain metabolic patterns diverged between animals. There was an elevation of basal ganglia Cho/Cr four weeks post-inoculation in 2 animals that developed SIV encephalitis (p = 0.022). Metabolite ratios averaged across all 8 animals were not significantly different from baseline at any time point after 2 weeks post inoculation. However, linear regression analysis on all 8 animals revealed a positive correlation between a change in frontal lobe Cho/Cr and plasma viral load (P < 0.001, R = 0.80), and a negative correlation between NAA/Cr in the basal ganglia and the plasma viral load (P < 0.02, R = -0.73). No MRI abnormalities were detected at any time.
After infection with SIV, macaque brain metabolism changes in a complex manner that is dependent on brain region, host factors and viral load. An elevation of basal ganglia Cho/Cr 4 weeks after SIV infection may be marker of a propensity to develop SIV encephalitis. Elevations of Cho/Cr, often observed in CNS inflammation, were associated with increased plasma viral load during acute and chronic infection. Evidence of neuronal injury in the basal ganglia was associated with increased plasma viral load in the chronic stage of infection. These observations support the use of drugs capable of controlling the viral replication and trafficking of virus into the CNS, and may help explain the reduction in incidence of HIV-associated dementia in the era of HAART despite the inability of most of those drugs to effectively enter the CNS.
The pathogenesis of brain injury in HIV infection remains incompletely understood. Elucidation of the pathogenesis of HIV brain injury is confounded by major uncertainties in humans, such as time of infection, variable treatments, and lack of access to brain tissue for evaluation. Neuroimaging has helped in understanding HIV related brain injury, and in recent years in vivo 1H MR spectroscopy has emerged as amongst the most informative method [1–11]. Brain MRS abnormalities in HIV have been widely reported, but studies have been limited to the chronic stages of HIV infection. To our knowledge, only one longitudinal MRS study of untreated, chronically HIV infected subjects have been reported . Brain abnormalities that may occur during the acute and subacute stages as well as their relationship to chronic HIV infection are unknown.
The SIV-infected macaque is an excellent animal model for studying the neuropathogenesis of HIV-related brain injury [13, 14], and 1H MRS may be used repeatedly in the same animal to follow brain abnormalities from early to late stages. In vivo macaque brain 1H MR spectra are similar to humans , and post mortem MRS studies from SIV-infected macaques have revealed metabolic abnormalities similar to those observed in chronically HIV-infected human brains by in vivo MRS [15, 16]. Significantly, cerebral injury is observed by in vivo 1H MRS  as well as by in vitro 1H MRS and neuropathology shortly after SIV infection [15, 16]. It is not known whether full recovery occurs, or whether these cerebral abnormalities persist into the subacute and chronic periods. One puzzle is that while virtually all SIV-infected macaques demonstrate cerebral injury acutely, fewer than a third ultimately develop SIV encephalitis (SIVE) .
Our previous observations of early brain injury in the SIV-infected macaque led to the investigation reported here [15, 16]. Our previous MRS studies were performed only on post mortem frontal cortex samples using solution 1H MRS of brain extracts  or high resolution magic angle spinning 1H MRS and neurohistochemistry of brain tissue samples . Those studies revealed evidence of frontal cortex neuronal injury with declines of the MRS neuronal marker N-acetylaspartate (NAA) [15, 16], and the neurohistochemcial neuronal markers synaptophysin and calbindin.  An important limitation of this previous work was that the brain samples were only from animals that had been euthanized within 2 weeks of infection, or at terminal AIDS. Thus, the events that may occur in the brain and are detectable by MRS between the very early and late periods of infection were unknown, and form, in part, the rationale for the present study design. Another issue arising from our previous in vitro studies was that we failed to detect expected increases in the choline-containing compounds (Cho) and myo-inositol (MI) that are commonly seen HIV infected patients [5–11].
In the study that we report here, we sought to understand whether brain injury in the SIV-infected macaque is detectable by in vivo 1H MRS in the subacute and chronic periods after infection, whether there are metabolic brain markers that predict the development of SIV encephalitis, and whether there are relationships between traditional clinical markers and brain MRS abnormalities. In a cohort of 8 macaques, we noninvasively evaluated the effect of SIVmac251 infection on the macaque brain by MRI and 1H MRS in a prospective, longitudinal manner.
SIV-infected macaque clinical and histopathological data
Age at death
Reason for euthanasia
1119 days est
Weight loss; mild diarrhea
Moderate SIVE; meningo-encephalomyelitis due to CMV
Orchitis due to CMV; enterotyphlocolitis
Weight loss; severe diarrhea
SIV giant cell pneumonia and PCP; mild enteritis
756 days est
Weight loss; diarrhea; anorexia
Mild perivascular accumulations of macrophages
Mild PCP and CMV in lung; glomerulonephritis
1254 days est
Severe oral disease
Mild perivascular edema
Ulcerative gingivitis and osteomyelitis; myocarditis
Epistaxis; respiratory disease
No significant CNS pathology
1694 days est
Termination of study
No significant CNS pathology
Vegetative endocarditis; fibrinous pleuritis
Termination of study
No significant CNS pathology
Termination of study
No significant CNS pathology
Vegetative endocarditis; severe protozoal gastritis
We found in this cohort a significant increase in frontal lobe Cho/Cr 2 weeks post inoculation (p < 0.05), a time coincident with viral neuroinvasion and increased numbers of perivascular macrophages [5, 19, 20]. These changes were also observed in the entire 15 animal cohort of the acute SIV infection study . This was followed by a decrease to below baseline at four weeks post inoculation (p < 0.01) as shown in figure 2. Subsequent to the acute period, some variation in Cho/Cr with time is apparent in figure 2, but we found no statistically significant difference between pre-infection mean values and any other post infection time point mean values in any of the brain regions. We did not detect statistically significant differences in NAA/Cr (figure 3) and MI/Cr (figure 4) in any of the brain regions under investigation after SIV infection compared to pre-infection values at any time point. In the 15 animal cohort studied during the first month after SIV infection, we detected statistically significant transient decline in NAA/Cr and an elevation in MI/Cr in the frontal cortex.  Restricting data analysis to the 8 animals followed longitudinally did not provide sufficient statistical power to detect significant changes in NAA/Cr or MI/Cr.
We did not detect other correlations between brain metabolite ratios and other blood/plasma measurements. In particular, we did not find a correlation between lymphocyte subsets (CD4+, CD8+) and brain MRS measurements. However, we did observe substantial variations in the levels of these lymphocyte subsets over time in the individual macaques. The most notable changes were declines in CD4+ lymphocytes to very low levels in the 2 animals that developed SIVE.
This is the first longitudinal neuroimaging study of human or nonhuman primates that begins before infection by an immunodeficiency virus, and continues through to the development of encephalitis. In a cohort of 8 rhesus macaques, we serially performed in vivo 1H MR spectroscopy and MRI with the goals of demonstrating whether brain injury in the SIV-infected macaque is detectable noninvasively, whether there are metabolic brain markers that predict the development of SIV encephalitis, and whether there are relationships between traditional clinical markers and brain 1H MRS abnormalities. While MRI appeared normal, novel metabolic abnormalities were observed, and they provide new insights into the response of the CNS to SIV infection that are relevant to HIV infection in humans.
The 1H MRS changes seen shortly after infection were expected. Previous work from our laboratory documented similar findings by MRS both in vivo  and in post mortem studies [15, 16]. Our observations during the subacute and chronic stages of SIV infection are new. Our most interesting finding was an elevation of Cho/Cr in the basal ganglia four weeks post-inoculation in the 2 animals destined to develop SIVE, whereas the other 6 animals had basal ganglia Cho/Cr values below baseline (figure 5).
SIV-induced neuropathological changes are variable with SIV encephalitis developing in 25% of infected macaques , similar to the incidence of encephalitis in HIV-infected humans, and the rate of SIVE in the present study. It is not clear why there is a spectrum of individual responses to infection with the same virus. The most likely explanations include viral mutation and the differences in host factors. Throughout the course of infection there is a high rate of mutation [21–24]. Our data supports an important role for host factors; at 4 weeks pi, when minimal viral mutation is expected, we found a clear difference in the basal ganglia Cho/Cr ratio between those macaques destined to develop SIVE and the others.
We suggest that the observation of persistent basal ganglia Cho/Cr elevation during the first month after infection is a marker of host susceptibility to SIVE. If confirmed, it may have important implications for design of further research, and potentially in the clinical management of patients. To our knowledge, the only other biomarker with the potential to predict encephalitis is elevated levels of macrophage chemoattractant protein-1 (MCP-1) in the CSF for development of SIVE . However, the MCP-1 finding was observed in an accelerated SIVE model that employs 2 viruses, results in a high rate of SIVE, and is quite different from the human situation. If persistence of elevated cerebral Cho/Cr is found to also be a predictor of a neurocognitive disorder in HIV-infected patients it could become an important clinical tool. For example, it may be used to identify individuals that may benefit from early, CNS-targeted or more aggressive administration of antiviral, anti-inflammatory, and neuroprotective agents.
Prior studies have demonstrated viral neuroinvasion in the weeks following infection [20, 26]. Brain abnormalities have been documented by in vivo 1H MRS , in vitro 1H MRS [15, 16], and neuropathology  in post-mortem tissues obtained within 2 weeks of infection. In the present study, we again observed abnormalities in vivo, specifically, elevation of frontal lobe Cho/Cr at the time of peak viremia (2 weeks pi), and a diminution of this ratio to below baseline at 4 weeks pi, after the immune system responded to the virus. An elevation of Cho/Cr is often observed in CNS inflammatory processes, and is seen in HIV infected patients before evidence of neuronal injury or neurocognitive symptoms [2, 4, 5, 27]. While a marked astrogliosis was observed in post-mortem tissue , elevations of the choline-containing metabolites in the in vitro MR spectra were not [15, 16]. Thus, in vivo Cho/Cr elevation appears to be related to astrogliosis, but levels of choline-containing compounds measured by MRS in vitro do not correlate. These findings are curious, and suggest that there is a poorly understood contribution to the Cho resonance measured by 1H MRS in vivo that requires further study.
Our observation of a positive linear correlation between plasma viral load and changes in frontal Cho/Cr during both the acute and chronic periods (figure 6a) is a new finding that may help to illuminate the CNS response to SIV. The brain viral inflammatory process induced by the virus may progress in at least 2 ways . The virus may enter the CNS shortly after infection, and continue to replicate there, producing a chronic, progressive inflammatory process that ultimately leads to neurodegeneration. Alternatively, virus may be largely cleared from the CNS after the initial viremia is controlled by the immune system, and cerebral inflammation returns only when there is loss of immunological control and recurrence of viremia. Our findings illustrated in figure 6a support a third proposition: brain inflammation tracks, and is directly related to blood levels of the virus which may peak from time to time, even before the onset of AIDS.
We did not detect reduced NAA/Cr as a function of time after infection in this longitudinal study (figure 3). We have previously observed declines in NAA/Cr 2 weeks after infection using in vivo  and in vitro 1H MRS [15, 16]. The most likely explanation is that SIVE was infrequent, and CNS disease was mild on average across the 8 animals. Thus NAA changes were too subtle to be detected in this small cohort by in vivo 1H MRS at 1.5 T. Indeed in our previous in vivo 1H MRS study , we found changes in NAA at 2 weeks, but a total of 15 animals were studied. This conclusion is also supported by human studies. The imaging protocol we employed in this study is identical to one used in a multicenter study of HIV infected subjects . That study detected a small difference in NAA/Cr, but required 15 HIV- and 38 neurosymptomatic, HIV+ subjects . Other in vivo MRS human studies demonstrating decreased NAA/Cr performed at 1.5 T also employed larger numbers and more advanced disease [1–3, 6, 8, 10, 27, 29, 30].
Variable progression of CNS disease in individual primates may also explain our inability to detect NAA/Cr change as a function of time after infection. If CNS injury in AIDS is characterized by different rates of neuronal injury progression alternating with periods of remission, the averaging of measurements at specific time points within a small cohort would mask evidence of brain injury. We mitigated the effects of temporal averaging by comparing brain metabolite levels with plasma viral load in individual animals, and found evidence of brain injury in the subacute and chronic periods of infection. As illustrated in figures 6a and 6b, SIV viremia significantly correlated with elevated frontal lobe Cho/Cr and decreased basal ganglia NAA/Cr. These correlations between plasma viral load and brain metabolites during the chronic phase of SIV infection suggests that CNS injury is dependent on the presence of the virus, most likely transmitted into the CNS by the trafficking of SIV-infected monocytes [19, 31–33].
The issue of variable response by different brain regions in response to SIV infection merits comment. Such variation in HIV-infected individuals has been reported by many groups [4–11]. We also find regional variations in the SIV infected macaque brain. We found that at 2 weeks pi the changes in Cho/Cr ratio appear greater in the frontal cortex than other areas. We do not know the situation in the human condition because such studies have not been reported in the early post infection stage. After the 2 week period, neuronal injury was more evident in basal ganglia than in other brain regions in the macaque, similar to human studies . It is possible that the tropism of the virus may change with time. That is, it is possible that early metabolic changes are prominent in the cortical regions and only later are they more prominent in the basal ganglia.
We monitored the brains of SIV-infected rhesus macaques with in vivo 1H MR spectroscopy longitudinally for up to two years. While no MRI abnormalities were detected, metabolic changes were observed by MRS. During the first 2 weeks of infection, we observed stereotypical brain MRS abnormalities. Thereafter we found a divergence in brain metabolic patterns amongst the animals. We found that an elevation of Cho/Cr in the basal ganglia four weeks after inoculation identified animals destined to develop SIVE, an observation that may have important clinical implications. Beyond the 2 week post inoculation, we did not find statistically significant differences in metabolite ratios averaged across all 8 animals between baseline and any specific time point. Yet we found a statistically significant positive correlation between frontal cortex Cho/Cr and viral load, and a statistically significant negative correlation between basal ganglia NAA/Cr and viral load. Thus, both elevations of the Cho/Cr ratio, often observed in CNS inflammatory processes, and evidence of neuronal injury, reduced NAA/Cr, were associated with increased plasma viral load. These observations indicate brain metabolic changes in the SIV infected macaque are driven by plasma viral load, and not by time after infection. Our findings that metabolic indicators of both cerebral inflammation and neuronal injury correlate with viral levels in the periphery also underscore the need to employ therapeutic regimens capable of controlling the propagation and trafficking of virus into the CNS. It may also help explain the reduction in incidence of HIV-associated dementia in the era of HAART despite the inability of most of those drugs to effectively enter the CNS.
Materials and methods
Animals and viral inoculation
Eight juvenile rhesus macaques (Macaca mulatta) were inoculated intravenously with SIVmac251 (50 ng p27/kg) . Animals were housed at the New England Primate Research Center, Southborough, MA and transported to the MGH NMR Center, Charlestown, MA for imaging. In preparation for imaging, the animals were initially tranquilized with ketamine or telazol and anesthetized with sodium pentobarbital. All animals were housed according to the standards of the American Association for Accreditation of Laboratory Animal Care. Investigators abided by the Guide for the Care and Use of Laboratory Animals of the Institute of Laboratory Animal resources, National Research Council. Animals were euthanized by an overdose of sodium pentabarbitol when they reached terminal AIDS or at the 2-year end point of the study. Postmortem pathological examinations were performed on all animals. The determination of encephalitis was based upon the presence of perivascular macrophages and multinucleated giant cells in the brain and detection of viral nucleic acids by in situ hybridization of three different brain regions, as described below.
Magnetic resonance imaging and spectroscopy
Each macaque had MRI and MRS performed before infection, and at multiple time points after being inoculated with SIVmac251. All macaques were scanned at 2 weeks post inoculation (11 days post inoculation (dpi) or 13 dpi), 4 weeks post inoculation (25 dpi or 27 dpi), 3 months post inoculation (mpi), 13 mpi, 15 mpi, 17 mpi, 19 mpi and 24 mpi. Since no study of this type had ever been reported, the rationale for this imaging schedule was based on our previous limited investigations of post mortem brain samples [15, 16]. We define 3 time periods with respect to infection: acute (within a month), subacute (between 1 and 3 months), chronic periods (beyond 3 months). Brain imaging was performed on a clinical 1.5 Tesla General Electric (Milwaukee, Wisconsin) Signa scanner with operating system Horizon 5.6 or 8.3, and a linear extremity coil.
The MRI portion of the exam consisted of T1 weighted sagittal images, followed by dual-echo, proton-density and T2 weighted axial images. Axial images were used to localize a 1.5 cm × 1.5 cm × 1.5 cm spectroscopy voxel in 3 locations: frontal cortex with the voxel centered on the interhemispheric fissure; deep white matter with the voxel centered on centrum semiovale; and basal ganglia with the voxel centered on the putamen. On repeat imaging, the animal head was positioned as in the previous study using three-plane scout imaging and iterative repositioning. In this manner, voxel placement was highly reproducible. With the exception of a slightly smaller voxel size, the MR spectroscopy protocol was identical to the one employed in multicenter human HIV studies that is characterized by high intersite and temporal reproducibility .
After animal imaging, MRS was performed on a phantom containing known concentrations of major brain metabolites (N-acetylaspartate, creatine, choline and myo-inositol). Phantom MR spectral data was employed to assess instrument stability. The protocol uses automated PROBE-P spectroscopy package, which consists of a PRESS sequence (TE = 35 msec, TR = 3000 msec) with CHESS water suppression [35, 36].
All spectra were processed off-line with the SAGE-GE spectral analysis program  to determine intensities of N-acetylaspartate (NAA), choline-containing compounds (Cho), and myoinositol (MI) resonances, relative to the creatine/phosphocreatine (Cr) resonance which served as internal intensity reference.
Plasma viral loads
Virion associated SIV RNA in plasma was quantified by using a real-time reverse transcription-PCR assay on an Applied Biosystems Prism 7700 sequence detection system as described previously [38, 39]. Results are averages of duplicate determinations. Analyses of viral RNA levels were performed by Drs. Jeffrey Lifson and Michael Piatak at SAIC-Frederick.
In situ hybridization
We examined frontal cortex, basal ganglia, and hippocampus/temporal cortex by SIV riboprobe in situ hybridization (ISH) for viral nucleic acid, as previously described [19, 40]. The ISH utilizes a DIG-labeled antisense riboprobe provided by Drs. V. Hirsch and C. Brown (National Institutes of Health, Rockville, MD) . Tissues were microwave pretreated and hybridized overnight at 45°C with 10 ng of antisense riboprobe. Hybridized probe was detected with alkaline phosphatase-conjugated anti-DIG antibody using standard immunologic methods. Controls consisted of sense probes, which had been labeled with digoxigenin at the same time as the anti-sense probe, and matched tissues from uninfected, age-matched control macaques.
Lymphocytes were isolated from blood and stained for flow cytometric analysis as previously described . Samples were immunoreacted with monoclonal antibodies against human CD4 (Ortho Diagnostics), CD8 (Becton Dickinson), and anti-rhesus CD3 (courtesy of J. Wong, Mass General Hospital) directly conjugated to either FITC, PE, PerCP, or APC. Samples were analyzed using a Vantage flow cytometer and Cell Quest Software (Becton Dickinson).
T tests assuming equal variances were used in comparisons between encephalitic and non-encephalitic animals. Prior to this, the validity of assuming equal variances was assessed. Correlations between cerebral metabolite ratios, flow cytometry, and SIV plasma viral load were calculated by regression analysis after adjusting all values relative to baseline measurements. Additionally ANOVA and Student-Newman-Keuls tests were utilized for the determination of trends.
This work was supported by NIH grants RR13213 (RGG), NS34626 (RGG), NS30769 (AAL), MH61192 (AAL), MH45294 (EM) and RR00168-39 (N.E.P.R.C.) The MGH NMR Center is also supported by P41RR14075 and the Mental Illness and Neuroscience Discovery (MIND) Institute. We wish to thank Drs. Angela Carville and Elizabeth Ludlage for veterinary care, Ernest Neale for veterinary technical assistance, Elizabeth Curran and Mike O'Connell for pathology support, and Kathy George for flow cytometric analysis.
- Menon DK, Ainsworth JG, Cox IJ, Coker RC, Sargentoni J, Coutts GA, Baudouin CJ, Kocsis AE, Harris JR: Proton MR spectroscopy of the brain in AIDS dementia complex. J Comput Assist Tomogr. 1992, 16: 538-542.View ArticlePubMedGoogle Scholar
- Jarvik JG, Lenkinski RE, Grossman RI, Gomori JM, Schnall MD, Frank I: Proton MR spectroscopy of HIV-infected patients: characterization of abnormalities with imaging and clinical correlation. Radiology. 1993, 186: 739-744.View ArticlePubMedGoogle Scholar
- Meyerhoff DJ, MacKay S, Bachman L, Poole N, Dillon WP, Weiner MW, Fein G: Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: in vivo 1H magnetic resonance spectroscopic imaging. Neurology. 1993, 43: 509-515.View ArticlePubMedGoogle Scholar
- Barker PB, Lee RR, McArthur JC: AIDS dementia complex: evaluation with proton MR spectroscopic imaging. Radiology. 1995, 195: 58-64.View ArticlePubMedGoogle Scholar
- Tracey I, Carr CA, Guimaraes AR, Worth JL, Navia BA, Gonzalez RG: Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study. Neurology. 1996, 46: 783-788.View ArticlePubMedGoogle Scholar
- Laubenberger J, Haussinger D, Bayer S, Thielemann S, Schneider B, Mundinger A, Hennig J, Langer M: HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology. 1996, 199: 805-810.View ArticlePubMedGoogle Scholar
- Lopez-Villegas D, Lenkinski RE, Frank I: Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 1997, 94: 9854-9859. 10.1073/pnas.94.18.9854.PubMed CentralView ArticlePubMedGoogle Scholar
- Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G: Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology. 1999, 52: 995-1003.View ArticlePubMedGoogle Scholar
- Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E: Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology. 1999, 52: 100-108.View ArticlePubMedGoogle Scholar
- Suwanwelaa N, Phanuphak P, Phanthumchinda K, Suwanwela NC, Tantivatana J, Ruxrungtham K, Suttipan J, Wangsuphachart S, Hanvanich M: Magnetic resonance spectroscopy of the brain in neurologically asymptomatic HIV-infected patients. Magn Reson Imaging. 2000, 18: 859-865. 10.1016/S0730-725X(00)00173-9.View ArticlePubMedGoogle Scholar
- Lee PL, Yiannoutsos CT, Ernst T, Chang L, Marra CM, Jarvik JG, Richards TL, Kwok EW, Kolson DL, Simpson D, Tang CY, Schifitto G, Ketonen LM, Meyerhoff DJ, Lenkinski RE, Gonzalez RG, Navia BA: A multi-center 1H MRS study of the AIDS dementia complex: Validation and preliminary analysis. J Magn Reson Imaging. 2003, 17: 625-633. 10.1002/jmri.10295.View ArticlePubMedGoogle Scholar
- McConnell JR, Swindells S, Ong CS, Gmeiner WH, Chu WK, Brown DK, Gendelman HE: Prospective utility of cerebral proton magnetic resonance spectroscopy in monitoring HIV infection and its associated neurological impairment. AIDS Res Hum Retroviruses. 1994, 10: 977-982.View ArticlePubMedGoogle Scholar
- Burudi EME, Fox Howard S.: Simian Immunodeficiency Virus Model of HIV-Induced Central Nervous System Dysfunction. Adv. Virus Reaserch. 2001, 56: 435-468. 10.1016/S0065-3527(01)56035-2.View ArticleGoogle Scholar
- Greco JB, Sakaie KE, Aminipour S, Lee PL, Chang LL, He J, Westmoreland S, Lackner AA, Gonzalez RG: Magnetic resonance spectroscopy: an in vivo tool for monitoring cerebral injury in SIV-infected macaques. J Med Primatol. 2002, 31: 228-236. 10.1034/j.1600-0684.2002.02009.x.View ArticlePubMedGoogle Scholar
- Tracey I, Lane J, Chang I, Navia B, Lackner A, Gonzalez RG: 1H magnetic resonance spectroscopy reveals neuronal injury in a simian immunodeficiency virus macaque model. J Acquir Immune Defic Syndr Hum Retrovirol. 1997, 15: 21-27.View ArticlePubMedGoogle Scholar
- Gonzalez RG, Cheng LL, Westmoreland SV, Sakaie KE, Becerra LR, Lee PL, Masliah E, Lackner AA: Early brain injury in the SIV-macaque model of AIDS. Aids. 2000, 14: 2841-2849. 10.1097/00002030-200012220-00005.View ArticlePubMedGoogle Scholar
- Greco JB, Sakaie KE, He J, Aminipour S, Lee PL, Cheng LL, Westmoreland S, Lackner A, Gonzalez RG: In vivo detection of reversible neurochemical changes during acute SIV infection by magnetic resonance spectroscopy. J Neurovirol. 2002, 8 (Suppl 1): 94.Google Scholar
- Westmoreland SV, Halpern E, Lackner AA: Simian immunodeficiency virus encephalitis in rhesus macaques is associated with rapid disease progression. J Neurovirol. 1998, 4: 260-268.View ArticlePubMedGoogle Scholar
- Orandle MS, Williams KC, MacLean AG, Westmoreland SV, Lackner AA: Macaques with rapid disease progression and simian immunodeficiency virus encephalitis have a unique cytokine profile in peripheral lymphoid tissues. J Virol. 2001, 75: 4448-4452. 10.1128/JVI.75.9.4448-4452.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Lane JH, Sasseville VG, Smith MO, Vogel P, Pauley DR, Heyes MP, Lackner AA: Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation. J Neurovirol. 1996, 2: 423-432.View ArticlePubMedGoogle Scholar
- Pelletier E, Saurin W, Cheynier R, Letvin NL, Wain-Hobson S: The tempo and mode of SIV quasispecies development in vivo calls for massive viral replication and clearance. Virology. 1995, 208: 644-652. 10.1006/viro.1995.1195.View ArticlePubMedGoogle Scholar
- Burns DP, Desrosiers RC: Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol. 1991, 65: 1843-1854.PubMed CentralPubMedGoogle Scholar
- Mansky LM, Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995, 69: 5087-5094.PubMed CentralPubMedGoogle Scholar
- Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995, 267: 483-489.View ArticlePubMedGoogle Scholar
- Zink MC, Coleman GD, Mankowski JL, Adams RJ, Tarwater PM, Fox K, Clements JE: Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. J Infect Dis. 2001, 184: 1015-1021. 10.1086/323478.View ArticlePubMedGoogle Scholar
- Lackner AA, Vogel P, Ramos RA, Kluge JD, Marthas M: Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus. Am J Pathol. 1994, 145: 428-439.PubMed CentralPubMedGoogle Scholar
- Chong WK, Sweeney B, Wilkinson ID, Paley M, Hall-Craggs MA, Kendall BE, Shepard JK, Beecham M, Miller RF, Weller IV, et al.: Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology. 1993, 188: 119-124.View ArticlePubMedGoogle Scholar
- Gartner S: HIV infection and dementia. Science. 2000, 287: 602-604. 10.1126/science.287.5453.602.View ArticlePubMedGoogle Scholar
- Moller HE, Vermathen P, Lentschig MG, Schuierer G, Schwarz S, Wiedermann D, Evers S, Husstedt IW: Metabolic characterization of AIDS dementia complex by spectroscopic imaging. J Magn Reson Imaging. 1999, 9: 10-18. 10.1002/(SICI)1522-2586(199901)9:1<10::AID-JMRI2>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Meyerhoff DJ, MacKay S, Poole N, Dillon WP, Weiner MW, Fein G: N-acetylaspartate reductions measured by 1H MRSI in cognitively impaired HIV-seropositive individuals. Magn Reson Imaging. 1994, 12: 653-659. 10.1016/0730-725X(94)92460-0.View ArticlePubMedGoogle Scholar
- Williams K, Schwartz A, Corey S, Orandle M, Kennedy W, Thompson B, Alvarez X, Brown C, Gartner S, Lackner A: Proliferating cellular nuclear antigen expression as a marker of perivascular macrophages in simian immunodeficiency virus encephalitis. Am J Pathol. 2002, 161: 575-585.PubMed CentralView ArticlePubMedGoogle Scholar
- Orandle MS, MacLean AG, Sasseville VG, Alvarez X, Lackner AA: Enhanced expression of proinflammatory cytokines in the central nervous system is associated with neuroinvasion by simian immunodeficiency virus and the development of encephalitis. J Virol. 2002, 76: 5797-5802. 10.1128/JVI.76.11.5797-5802.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Fischer-Smith T, Croul S, Sverstiuk AE, Capini C, L'Heureux D, Regulier EG, Richardson MW, Amini S, Morgello S, Khalili K, Rappaport J: CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol. 2001, 7: 528-541. 10.1080/135502801753248114.View ArticlePubMedGoogle Scholar
- Kodama T, Mori K, Kawahara T, Ringler DJ, Desrosiers RC: Analysis of simian immunodeficiency virus sequence variation in tissues of rhesus macaques with simian AIDS. J Virol. 1993, 67: 6522-6534.PubMed CentralPubMedGoogle Scholar
- Bottomley PA: Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 1987, 508: 333-348.View ArticlePubMedGoogle Scholar
- Haase A, Frahm J, Hanicke W, Matthaei D: 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol. 1985, 30: 341-344. 10.1088/0031-9155/30/4/008.View ArticlePubMedGoogle Scholar
- Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE: Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med. 1994, 31: 365-373.View ArticlePubMedGoogle Scholar
- Suryanarayana K, Wiltrout TA, Vasquez GM, Hirsch VM, Lifson JD: Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res Hum Retroviruses. 1998, 14: 183-189.View ArticlePubMedGoogle Scholar
- Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, Arthur LO, Johnson RP: Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol. 1998, 72: 1431-1437.PubMed CentralPubMedGoogle Scholar
- Wykrzykowska JJ, Rosenzweig M, Veazey RS, Simon MA, Halvorsen K, Desrosiers RC, Johnson RP, Lackner AA: Early regeneration of thymic progenitors in rhesus macaques infected with simian immunodeficiency virus. J Exp Med. 1998, 187: 1767-1778. 10.1084/jem.187.11.1767.PubMed CentralView ArticlePubMedGoogle Scholar
- Hirsch VM, Adger-Johnson D, Campbell B, Goldstein S, Brown C, Elkins W, Montefiori DC: A Molecularly Cloned Pathogenic, neutralization-resistant Simian Immunodeficiency Virus, SIVsmmE543-3. Virology. 1997, 71: 1608-1620.Google Scholar
- Veazey RS, Tham IC, Mansfield KG, DeMaria M, Forand AE, Shvetz DE, Chalifoux LV, Sehgal PK, Lackner AA: Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol. 2000, 74: 57-64. 10.1128/JVI.74.23.11001-11007.2000.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.